The mechanism of action of antiviral drugs is mainly to inhibit the entry of viral particles into host cells and to inhibit the early stages of viral replication. There is also an inhibitor of DNA polymerase, which is mainly due to its ability to inhibit viral coding. At present, new antiviral drugs are actively seeking host factors, both in the initial stage of viral infection and in the later stages of nuclear transport of viral RNP complexes, to produce new drugs with new modes of action without drug resistance.

The global Novel Antiviral Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Novel Antiviral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Antiviral Drugs.

Report Scope

The Novel Antiviral Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Novel Antiviral Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Novel Antiviral Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Novel Antiviral Drugs Market Report

Report Metric	Details
Report Name	Novel Antiviral Drugs Market
CAGR	5%
Segment by Type	Reverse Transcriptase Inhibitors Protease Inhibitors Fusion Inhibitors Immune System Modulators Other
Segment by Application	Hepatitis Therapeutics HIV/AIDS Therapeutics Herpes Therapeutics Influenza Therapeutics Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche Holding AG, GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Johnson & Johnson, Merck & Co, Novartis, Dr Reddy’s, Gilead Sciences, Aurobindo Pharma, Cipla
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Novel Antiviral Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Novel Antiviral Drugs Market report?

Ans: The main players in the Novel Antiviral Drugs Market are Roche Holding AG, GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Johnson & Johnson, Merck & Co, Novartis, Dr Reddy’s, Gilead Sciences, Aurobindo Pharma, Cipla

What are the Application segmentation covered in the Novel Antiviral Drugs Market report?

Ans: The Applications covered in the Novel Antiviral Drugs Market report are Hepatitis Therapeutics, HIV/AIDS Therapeutics, Herpes Therapeutics, Influenza Therapeutics, Other

What are the Type segmentation covered in the Novel Antiviral Drugs Market report?

Ans: The Types covered in the Novel Antiviral Drugs Market report are Reverse Transcriptase Inhibitors, Protease Inhibitors, Fusion Inhibitors, Immune System Modulators, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Novel Antiviral Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Reverse Transcriptase Inhibitors

1.2.3 Protease Inhibitors

1.2.4 Fusion Inhibitors

1.2.5 Immune System Modulators

1.2.6 Other

1.3 Market by Application

1.3.1 Global Novel Antiviral Drugs Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hepatitis Therapeutics

1.3.3 HIV/AIDS Therapeutics

1.3.4 Herpes Therapeutics

1.3.5 Influenza Therapeutics

1.3.6 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Novel Antiviral Drugs Market Perspective (2019-2030)

2.2 Novel Antiviral Drugs Growth Trends by Region

2.2.1 Global Novel Antiviral Drugs Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Novel Antiviral Drugs Historic Market Size by Region (2019-2024)

2.2.3 Novel Antiviral Drugs Forecasted Market Size by Region (2025-2030)

2.3 Novel Antiviral Drugs Market Dynamics

2.3.1 Novel Antiviral Drugs Industry Trends

2.3.2 Novel Antiviral Drugs Market Drivers

2.3.3 Novel Antiviral Drugs Market Challenges

2.3.4 Novel Antiviral Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Novel Antiviral Drugs Players by Revenue

3.1.1 Global Top Novel Antiviral Drugs Players by Revenue (2019-2024)

3.1.2 Global Novel Antiviral Drugs Revenue Market Share by Players (2019-2024)

3.2 Global Novel Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Novel Antiviral Drugs Revenue

3.4 Global Novel Antiviral Drugs Market Concentration Ratio

3.4.1 Global Novel Antiviral Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Novel Antiviral Drugs Revenue in 2023

3.5 Novel Antiviral Drugs Key Players Head office and Area Served

3.6 Key Players Novel Antiviral Drugs Product Solution and Service

3.7 Date of Enter into Novel Antiviral Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Novel Antiviral Drugs Breakdown Data by Type

4.1 Global Novel Antiviral Drugs Historic Market Size by Type (2019-2024)

4.2 Global Novel Antiviral Drugs Forecasted Market Size by Type (2025-2030)

5 Novel Antiviral Drugs Breakdown Data by Application

5.1 Global Novel Antiviral Drugs Historic Market Size by Application (2019-2024)

5.2 Global Novel Antiviral Drugs Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Novel Antiviral Drugs Market Size (2019-2030)

6.2 North America Novel Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Novel Antiviral Drugs Market Size by Country (2019-2024)

6.4 North America Novel Antiviral Drugs Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Novel Antiviral Drugs Market Size (2019-2030)

7.2 Europe Novel Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Novel Antiviral Drugs Market Size by Country (2019-2024)

7.4 Europe Novel Antiviral Drugs Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Novel Antiviral Drugs Market Size (2019-2030)

8.2 Asia-Pacific Novel Antiviral Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Novel Antiviral Drugs Market Size by Region (2019-2024)

8.4 Asia-Pacific Novel Antiviral Drugs Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Novel Antiviral Drugs Market Size (2019-2030)

9.2 Latin America Novel Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Novel Antiviral Drugs Market Size by Country (2019-2024)

9.4 Latin America Novel Antiviral Drugs Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Novel Antiviral Drugs Market Size (2019-2030)

10.2 Middle East & Africa Novel Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Novel Antiviral Drugs Market Size by Country (2019-2024)

10.4 Middle East & Africa Novel Antiviral Drugs Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche Holding AG

11.1.1 Roche Holding AG Company Detail

11.1.2 Roche Holding AG Business Overview

11.1.3 Roche Holding AG Novel Antiviral Drugs Introduction

11.1.4 Roche Holding AG Revenue in Novel Antiviral Drugs Business (2019-2024)

11.1.5 Roche Holding AG Recent Development

11.2 GlaxoSmithKline

11.2.1 GlaxoSmithKline Company Detail

11.2.2 GlaxoSmithKline Business Overview

11.2.3 GlaxoSmithKline Novel Antiviral Drugs Introduction

11.2.4 GlaxoSmithKline Revenue in Novel Antiviral Drugs Business (2019-2024)

11.2.5 GlaxoSmithKline Recent Development

11.3 Bristol-Myers Squibb

11.3.1 Bristol-Myers Squibb Company Detail

11.3.2 Bristol-Myers Squibb Business Overview

11.3.3 Bristol-Myers Squibb Novel Antiviral Drugs Introduction

11.3.4 Bristol-Myers Squibb Revenue in Novel Antiviral Drugs Business (2019-2024)

11.3.5 Bristol-Myers Squibb Recent Development

11.4 AbbVie

11.4.1 AbbVie Company Detail

11.4.2 AbbVie Business Overview

11.4.3 AbbVie Novel Antiviral Drugs Introduction

11.4.4 AbbVie Revenue in Novel Antiviral Drugs Business (2019-2024)

11.4.5 AbbVie Recent Development

11.5 Johnson & Johnson

11.5.1 Johnson & Johnson Company Detail

11.5.2 Johnson & Johnson Business Overview

11.5.3 Johnson & Johnson Novel Antiviral Drugs Introduction

11.5.4 Johnson & Johnson Revenue in Novel Antiviral Drugs Business (2019-2024)

11.5.5 Johnson & Johnson Recent Development

11.6 Merck & Co

11.6.1 Merck & Co Company Detail

11.6.2 Merck & Co Business Overview

11.6.3 Merck & Co Novel Antiviral Drugs Introduction

11.6.4 Merck & Co Revenue in Novel Antiviral Drugs Business (2019-2024)

11.6.5 Merck & Co Recent Development

11.7 Novartis

11.7.1 Novartis Company Detail

11.7.2 Novartis Business Overview

11.7.3 Novartis Novel Antiviral Drugs Introduction

11.7.4 Novartis Revenue in Novel Antiviral Drugs Business (2019-2024)

11.7.5 Novartis Recent Development

11.8 Dr Reddy’s

11.8.1 Dr Reddy’s Company Detail

11.8.2 Dr Reddy’s Business Overview

11.8.3 Dr Reddy’s Novel Antiviral Drugs Introduction

11.8.4 Dr Reddy’s Revenue in Novel Antiviral Drugs Business (2019-2024)

11.8.5 Dr Reddy’s Recent Development

11.9 Gilead Sciences

11.9.1 Gilead Sciences Company Detail

11.9.2 Gilead Sciences Business Overview

11.9.3 Gilead Sciences Novel Antiviral Drugs Introduction

11.9.4 Gilead Sciences Revenue in Novel Antiviral Drugs Business (2019-2024)

11.9.5 Gilead Sciences Recent Development

11.10 Aurobindo Pharma

11.10.1 Aurobindo Pharma Company Detail

11.10.2 Aurobindo Pharma Business Overview

11.10.3 Aurobindo Pharma Novel Antiviral Drugs Introduction

11.10.4 Aurobindo Pharma Revenue in Novel Antiviral Drugs Business (2019-2024)

11.10.5 Aurobindo Pharma Recent Development

11.11 Cipla

11.11.1 Cipla Company Detail

11.11.2 Cipla Business Overview

11.11.3 Cipla Novel Antiviral Drugs Introduction

11.11.4 Cipla Revenue in Novel Antiviral Drugs Business (2019-2024)

11.11.5 Cipla Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

List of Tables

Table 1. Global Novel Antiviral Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Reverse Transcriptase Inhibitors

Table 3. Key Players of Protease Inhibitors

Table 4. Key Players of Fusion Inhibitors

Table 5. Key Players of Immune System Modulators

Table 6. Key Players of Other

Table 7. Global Novel Antiviral Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Novel Antiviral Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Novel Antiviral Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 10. Global Novel Antiviral Drugs Market Share by Region (2019-2024)

Table 11. Global Novel Antiviral Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 12. Global Novel Antiviral Drugs Market Share by Region (2025-2030)

Table 13. Novel Antiviral Drugs Market Trends

Table 14. Novel Antiviral Drugs Market Drivers

Table 15. Novel Antiviral Drugs Market Challenges

Table 16. Novel Antiviral Drugs Market Restraints

Table 17. Global Novel Antiviral Drugs Revenue by Players (2019-2024) & (US$ Million)

Table 18. Global Novel Antiviral Drugs Market Share by Players (2019-2024)

Table 19. Global Top Novel Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Antiviral Drugs as of 2023)

Table 20. Ranking of Global Top Novel Antiviral Drugs Companies by Revenue (US$ Million) in 2023

Table 21. Global 5 Largest Players Market Share by Novel Antiviral Drugs Revenue (CR5 and HHI) & (2019-2024)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Novel Antiviral Drugs Product Solution and Service

Table 24. Date of Enter into Novel Antiviral Drugs Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Novel Antiviral Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 27. Global Novel Antiviral Drugs Revenue Market Share by Type (2019-2024)

Table 28. Global Novel Antiviral Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 29. Global Novel Antiviral Drugs Revenue Market Share by Type (2025-2030)

Table 30. Global Novel Antiviral Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 31. Global Novel Antiviral Drugs Revenue Market Share by Application (2019-2024)

Table 32. Global Novel Antiviral Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 33. Global Novel Antiviral Drugs Revenue Market Share by Application (2025-2030)

Table 34. North America Novel Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. North America Novel Antiviral Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 36. North America Novel Antiviral Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 37. Europe Novel Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Europe Novel Antiviral Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 39. Europe Novel Antiviral Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 40. Asia-Pacific Novel Antiviral Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 41. Asia-Pacific Novel Antiviral Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 42. Asia-Pacific Novel Antiviral Drugs Market Size by Region (2025-2030) & (US$ Million)

Table 43. Latin America Novel Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Latin America Novel Antiviral Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 45. Latin America Novel Antiviral Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 46. Middle East & Africa Novel Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 47. Middle East & Africa Novel Antiviral Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 48. Middle East & Africa Novel Antiviral Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 49. Roche Holding AG Company Detail

Table 50. Roche Holding AG Business Overview

Table 51. Roche Holding AG Novel Antiviral Drugs Product

Table 52. Roche Holding AG Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 53. Roche Holding AG Recent Development

Table 54. GlaxoSmithKline Company Detail

Table 55. GlaxoSmithKline Business Overview

Table 56. GlaxoSmithKline Novel Antiviral Drugs Product

Table 57. GlaxoSmithKline Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 58. GlaxoSmithKline Recent Development

Table 59. Bristol-Myers Squibb Company Detail

Table 60. Bristol-Myers Squibb Business Overview

Table 61. Bristol-Myers Squibb Novel Antiviral Drugs Product

Table 62. Bristol-Myers Squibb Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 63. Bristol-Myers Squibb Recent Development

Table 64. AbbVie Company Detail

Table 65. AbbVie Business Overview

Table 66. AbbVie Novel Antiviral Drugs Product

Table 67. AbbVie Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 68. AbbVie Recent Development

Table 69. Johnson & Johnson Company Detail

Table 70. Johnson & Johnson Business Overview

Table 71. Johnson & Johnson Novel Antiviral Drugs Product

Table 72. Johnson & Johnson Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 73. Johnson & Johnson Recent Development

Table 74. Merck & Co Company Detail

Table 75. Merck & Co Business Overview

Table 76. Merck & Co Novel Antiviral Drugs Product

Table 77. Merck & Co Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 78. Merck & Co Recent Development

Table 79. Novartis Company Detail

Table 80. Novartis Business Overview

Table 81. Novartis Novel Antiviral Drugs Product

Table 82. Novartis Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 83. Novartis Recent Development

Table 84. Dr Reddy’s Company Detail

Table 85. Dr Reddy’s Business Overview

Table 86. Dr Reddy’s Novel Antiviral Drugs Product

Table 87. Dr Reddy’s Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 88. Dr Reddy’s Recent Development

Table 89. Gilead Sciences Company Detail

Table 90. Gilead Sciences Business Overview

Table 91. Gilead Sciences Novel Antiviral Drugs Product

Table 92. Gilead Sciences Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 93. Gilead Sciences Recent Development

Table 94. Aurobindo Pharma Company Detail

Table 95. Aurobindo Pharma Business Overview

Table 96. Aurobindo Pharma Novel Antiviral Drugs Product

Table 97. Aurobindo Pharma Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 98. Aurobindo Pharma Recent Development

Table 99. Cipla Company Detail

Table 100. Cipla Business Overview

Table 101. Cipla Novel Antiviral Drugs Product

Table 102. Cipla Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 103. Cipla Recent Development

Table 104. Research Programs/Design for This Report

Table 105. Key Data Information from Secondary Sources

Table 106. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Novel Antiviral Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Novel Antiviral Drugs Market Share by Type: 2023 VS 2030

Figure 3. Reverse Transcriptase Inhibitors Features

Figure 4. Protease Inhibitors Features

Figure 5. Fusion Inhibitors Features

Figure 6. Immune System Modulators Features

Figure 7. Other Features

Figure 8. Global Novel Antiviral Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global Novel Antiviral Drugs Market Share by Application: 2023 VS 2030

Figure 10. Hepatitis Therapeutics Case Studies

Figure 11. HIV/AIDS Therapeutics Case Studies

Figure 12. Herpes Therapeutics Case Studies

Figure 13. Influenza Therapeutics Case Studies

Figure 14. Other Case Studies

Figure 15. Novel Antiviral Drugs Report Years Considered

Figure 16. Global Novel Antiviral Drugs Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 17. Global Novel Antiviral Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 18. Global Novel Antiviral Drugs Market Share by Region: 2023 VS 2030

Figure 19. Global Novel Antiviral Drugs Market Share by Players in 2023

Figure 20. Global Top Novel Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Antiviral Drugs as of 2023)

Figure 21. The Top 10 and 5 Players Market Share by Novel Antiviral Drugs Revenue in 2023

Figure 22. North America Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. North America Novel Antiviral Drugs Market Share by Country (2019-2030)

Figure 24. United States Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Canada Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Europe Novel Antiviral Drugs Market Share by Country (2019-2030)

Figure 28. Germany Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. France Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. U.K. Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Italy Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Russia Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Nordic Countries Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Asia-Pacific Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Asia-Pacific Novel Antiviral Drugs Market Share by Region (2019-2030)

Figure 36. China Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Japan Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. South Korea Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Southeast Asia Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. India Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Australia Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Latin America Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Latin America Novel Antiviral Drugs Market Share by Country (2019-2030)

Figure 44. Mexico Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Brazil Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Middle East & Africa Novel Antiviral Drugs Market Share by Country (2019-2030)

Figure 48. Turkey Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Saudi Arabia Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 50. Roche Holding AG Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)

Figure 51. GlaxoSmithKline Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)

Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)

Figure 53. AbbVie Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)

Figure 54. Johnson & Johnson Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)

Figure 55. Merck & Co Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)

Figure 56. Novartis Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)

Figure 57. Dr Reddy’s Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)

Figure 58. Gilead Sciences Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)

Figure 59. Aurobindo Pharma Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)

Figure 60. Cipla Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

Antiviral Drugs Market

Influenza Diagnostics Market

Direct acting Antiviral Drugs Market

Influenza Antiviral Drugs Market

Antiviral Therapy Market

HIV Therapeutics Market

Protease Inhibitors Market

Hepatitis B Therapeutics Market

Anti Viral Coatings Market

Sterile and Antiviral Packaging Market

Specific Antiviral Drugs for COVID 19 Market

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions